Primer Consenso Nacional Intersociedades de Inmunización del Adulto. 2023

Las vacunas previenen millones de muertes cada año y su eficacia y seguridad han sido ampliamente establecidas. En términos económicos, la vacunación es una de las intervenciones sanitarias más costo efectivas, generando un importante ahorro y crecimiento económico que supone a largo plazo. Se ha demostrado que la vacunación de adultos disminuye la morbilidad y la mortalidad asociadas a enfermedades infecciosas prevenibles, reduciendo las complicaciones y las hospitalizaciones, incluidos los ingresos a las unidades de cuidados intensivos. Hemos elaborado este documento de consenso con el objeto de diseñar un esquema de vacunación pragmático, accesible y estandarizado del adulto, según categoría de riesgo y edad, sobre la base de la evidencia disponible de vacunas accesibles y nuevas vacunas habiendo utilizado el Tercer Consenso de la Sociedad Paraguaya de Infectología del 2019 como base para las recomendaciones finales.

SUMMARY Vaccines prevent millions of deaths each year, and their efficacy and safety have been widely established. In economic terms, vaccination is one of the most cost-effective health interventions, generating significant savings and long-term economic growth. Adult vaccination has been shown to decrease morbidity and mortality associated with preventable Infectious diseases, reducing complications and hospitalizations, including admissions to intensive care units. We have prepared this consensus document in order to design a pragmatic, accessible and standardized vaccination scheme for adults, according to risk category and age, based on the available evidence of available vaccines and new vaccines, having used the third consensus of the Paraguayan Infectious Diseases Society of 2019 as a basis for the final recommendations.

Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule

Abstract Given that the last notified case of poliomyelitis due to wild poliovirus type 2 was in 1999, in 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) of the World Health Organization (WHO) recommended the withdrawal of the type 2 component of oral polio vaccine (OPV) and the introduction of a bivalent OPV (bOPV) in all countries by 2016. WHO recommended also that the withdrawal should be preceded by the introduction of at least one dose of inactivated poliovirus vaccine (IPV) in routine immunization schedules. The introduction of IPV prior to the change of the bOPV in 2016 to trivalent OPV (tOPV) was based on the concept of ensuring that a substantial proportion of the population would be protected against type 2 polio after the removal of the type 2 OPV. However, the world's two producers of IPV (Bilthoven Biologicals and Sanofi) have faced problems in the production of this vaccine and therefore reported a reduction of the global supply of IPV. In response to the potential shortage of IPV, at a meeting held on March 10 2017, the SAGE and Technical Advisory Group (TAG) of the Pan American Health Organization (PAHO) urged the countries in the Latin American region to replace the routine administration of the full doses of inactivated polio vaccine (IPV-C) in the immunization schedule (administered by intramuscular route), administering a fraction of the full dose in two intradermal shots (IPV-f). The possibility of this strategy was analyzed by opinion leaders convened by the Paraguayan Society of Pediatrics with the support of the Latin American Society of Pediatric Infectious Diseases (SLIPE) and Latin American Association of Pediatrics (ALAPE). This document presents the results of the discussion.

Consideraciones referente a la posibilidad de introducir la dosis fraccionada de la vacuna antipoliomielitis inactivada en el calendario de Inmunizaciones del Niño Latinoamericano / Remarks on the possibility of the introduction of fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule

As last notified case of poliomyelitis due to wild poliovirus type 2 was 1999, in 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) of the World Health Organization (WHO) recommended the withdrawal of the type 2 component of oral polio vaccine (OPV) and the introduction of bivalent OPV (bOPV) in all countries by 2016. WHO recommended also that the withdrawal should be preceded by the introduction of at least one dose of inactivated poliovirus vaccine (IPV) in routine immunization schedules. The introduction of IPV prior to the change of the bOPV in 2016 to trivalent OPV (tOPV) was based on the concept of ensuring that a substantial proportion of the population would be protected against type 2 polio after the removal of the type 2 OPV. However, the world's two producers of IPV (Bilthoven Biologicals and Sanofi) have faced problems in the production of this vaccine and therefore reported reduction in IPV global supply. In response to the possible shortage of IPV, the SAGE and Technical Adviser Group (TAG) of the Pan American Health Organization (PAHO), in the meeting of March 10, 2017, has urged that countries in the Latinamerican region should replace the routine administration of the full doses of polio inactivated vaccine (IPV-C) in the immunization schedule (administered by intramuscular route) by the administration of a fraction of the full dose in two shots by intradermal route (IPV-f). The possibility of this strategy was analyzed by leaders of opinions gathered by the call of the Paraguayan Pediatric Society with the support of the Latin American Society of Pediatric Infectious Diseases (SLIPE) and Latin American Association of Pediatrics (ALAPE). The results of the discussion are presented in this document.

Brote de Parotiditis Vírica en el Liceo Militar de Acosta Ñu de junio a octubre del año 2016 / Outbreak of Viral Parotitis at the Acosta Ñu Military Academy from june to october 2016

Introducción: El presente estudio trata de un brote de parotiditis en un Liceo Militar que se inicia en junio del año 2016 y se prolonga hasta fines de octubre del mismo año. El objetivo fue describir las características epidemiológicas del brote. Métodos: Es observacional, retroprospectivo, de corte transverso de fichas clínicas de cadetes que constan en el archivo del Liceo Militar de Acosta Ñu que abarca el periodo junio a octubre del año 2016 y posterior entrevista a los afectados. Resultados: De 181 cadetes, todos masculinos, con edad media de 16 años, del Liceo Militar de Acosta Ñu. Se tomó como muestra a 115 cadetes (63%) presentaron parotiditis, sin afectación de las otras glándulas salivales. En 50 casos (44%) de forma bilateral y 64 casos (56%) unilateral. 23 cadetes (20%) presentaron complicaciones, como orquitis 22 (19%) todos unilaterales, pancreatitis 1. En ningún caso se presentó meningitis, encefalitis, miocarditis, todos sobrevivieron. De los cadetes afectados no fueron vacunados (SPR) 103 (90%), 8 (7%) recibieron una dosis y 2 (2.3%) dos dosis. Los casos ocurridos (63%) fue debida a la falta de vacunación completa (Triple Viral, 2 dosis) y a las condiciones de hacinamiento de los cadetes. Conclusión: El brote de parotiditis ocurrido en el Liceo Militar de Acosta Ñu, se caracterizó por la alta incidencia de contagios debido a la baja o nula cobertura vacunal y a las condiciones de hacinamiento de los cadetes. Por lo tanto recomendamos que al ingreso a toda institución que incluya residencia temporal o fija en condiciones de hacinamiento, la exigencia mínima debiera ser la presentación de un carnet de vacunación completo.

Introduction: This study describes an outbreak of mumps in a Military Academy that began in June 2016 and lasted until the end of October of the same year. Objective: To describe the epidemiological characteristics of the outbreak. Materials and Methods: This was an observational, retroprospective, cross-sectional review of the medical records of cadets at the Acosta Ñu Military Academy who presented for medical evaluation from June to October, 2016 and with subsequent interviews with identified patients with parotitis. Results: Of 181 cadets, all were male, with an average age of 16 years. We selected a sample of 115 cadets (63%) who presented parotiditis, without involvement of other salivary glands. In 50 cases (44%) the illness was bilateral and in 64 cases (56%), the illness was unilateral. 23 cadets (20%) presented complications, such as orchitis 22 (19%) all unilateral, and one patient had pancreatitis. No patient had meningitis, encephalitis, or myocarditis, and there were no deaths. Of the affected 103 (90%) cadets were not vaccinated with the measles-mumps-rubella (MMR) vaccine, 8 (7%) had received one dose and 2 (2.3%) received two doses. The cases that occurred (63%) were due to the lack of complete vaccination (MMR vaccine, 2 doses) and to the overcrowded conditions of the cadets. Conclusion: The Outbreak of parotitis, which occurred at Acosta Ñu Military Academy, was characterized by a high incidence of infections due to incomplete or no vaccination coverage and the overcrowded conditions of the cadets. Therefore, we recommend that upon admission to any institution that includes temporary or fixed residence in overcrowded conditions, the minimum requirement should be the presentation of a completed vaccination card.